ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Comparison of LENT, PROMISE, and RECLS scores in malignant pleural effusions.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMalignant pleural effusion (MPE) is an indicator of advanced malignancy associated with poor prognosis and increased symptom burden and healthcare costs. Predicting survival in patients with MPE is important for determining appropriate palliative management and the need for pleurodesis.
methodsThe data of 211 patients diagnosed with MPE between January 2012 and January 2024 were retrospectively analyzed. Patients were categorized into three groups: lung adenocarcinoma (LAC), non-adenocarcinoma lung tumors (NALC), and non-lung malignancies (NLM). LENT, PROMISE, and modified RECLS scores were calculated for all patients. Survival analyses were performed using ROC analysis, Kaplan-Meier curves, and Cox regression methods.
resultsAll scoring systems were significantly higher in patients who died at 1, 6, and 12 months compared with those who survived. RECLS demonstrated the highest discriminative ability for overall mortality prediction, with particularly improved performance at 6 and 12 months. The LENT score was also significantly associated with survival in the overall cohort as well as in the lung adenocarcinoma and non-lung malignancy subgroups. The PROMISE score showed lower predictive accuracy and did not outperform the other scoring systems. ECOG performance status was one of the strongest prognostic variables across all time periods.
conclusionRECLS and LENT appear to be more effective than PROMISE in predicting survival in patients with MPE. In particular, RECLS may serve as a reliable tool for predicting both early and late mortality and could contribute to clinical decision-making in the management of patients with malignant pleural effusion.
Indexed as
Identifiers
42174352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.